Premium
DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia
Author(s) -
Sligte Naomi E.,
Krumbholz Manuela,
Pastorczak Agata,
Scheijen Blanca,
Tauer Josephine T.,
Nowasz Christina,
Sonneveld Edwin,
Bock Geertruida H.,
Meeuwsende Boer Tiny G. J.,
Reijmersdal Simon,
Kuiper Roland P.,
Bradtke Jutta,
Metzler Markus,
Suttorp Meinolf,
Bont Evelina S. J. M.,
Leeuwen Frank N.
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12850
Subject(s) - cdkn2a , pax5 , medicine , blast crisis , immunology , disease , chronic myeloid leukaemia , cancer research , myeloid , oncology , b cell , cancer , antibody
Summary Early recognition of children with chronic phase chronic myeloid leukaemia ( CML ‐ CP ) at risk for developing a lymphoid blast crisis (Ly BC ) is desirable, because therapy options in CML ‐ L y BC are limited. We used Multiplex Ligation‐dependent Probe Amplification to determine whether B ‐cell lymphoid leukaemia‐specific copy number alterations ( CNA s) (e.g. IKZF 1 , PAX 5 , CDKN 2A deletions) could be detected in CML ‐ CP and may be used to predict disease progression to Ly BC . CNA s were detected in all patients with CML ‐Ly BC , but in none of the 77 patients with CML ‐ CP . Based on this study we conclude that CNA s remain a hallmark of disease progression.